Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Matthew T Roe, Paul W Armstrong, Keith AA Fox, Harvey D White, Dorairaj Prabhakaran, Shaun G Goodman, Jan H Cornel, Deepak L Bhatt, Peter Clemmensen, Felipe Martinez, Diego Ardissino, Jose C Nicolau, William E Boden, Paul A Gurbel, Witold Ruzyllo, Anthony J Dalby, Darren K McGuire, Jose L Leiva-Pons, Alexander Parkhomenko, Shmuel Gottlieb, Gracita O Topacio, Christian Hamm, Gregory Pavlides, Assen R Goudev, Ali Oto, Chuen-Den Tseng, Bela Merkely, Vladimir Gasparovic, Ramon Corbalan, Mircea Cinteză, R Craig McLendon, Kenneth J Winters, Eileen B Brown, Yuliya Lokhnygina, Philip E Aylward, Kurt Huber, Judith S Hochman, E Magnus Ohman
2012-10-04
Abstract:BackgroundThe effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. MethodsIn this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. ResultsAt a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05 …